ID

12765

Description

A Phase I, Multicenter, Open Label Study on the Effects of SNDX-275 on Expression of Biomarkers in Subjects With Newly Diagnosed Breast Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00754312

Lien

https://clinicaltrials.gov/show/NCT00754312

Mots-clés

  1. 21/12/2015 21/12/2015 -
Téléchargé le

21 décembre 2015

DOI

Pour une demande vous connecter.

Licence

Creative Commons BY 4.0

Modèle Commentaires :

Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.

Groupe Item commentaires pour :

Item commentaires pour :

Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.

Eligibility Breast Cancer NCT00754312

Eligibility Breast Cancer NCT00754312

Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
is scheduled for breast biopsy due to a suspicious mass palpable or ≥1 cm on mammogram
Description

breast biopsy; mammogram

Type de données

boolean

Alias
UMLS CUI [1]
C0405352
UMLS CUI [2]
C0024671
must be able to receive two doses of study medication 7 days apart prior to surgery
Description

Medication dose study

Type de données

boolean

Alias
UMLS CUI [1,1]
C3174092
UMLS CUI [1,2]
C0008972
has histologically confirmed invasive breast cancer with er positive, er and/or pr negative histology or triple negative (for er, pr, her-2) histology
Description

Invasive breast carcinoma

Type de données

boolean

Alias
UMLS CUI [1]
C0853879
has an ecog performance status ≤ 2
Description

ecog performance status

Type de données

boolean

Alias
UMLS CUI [1]
C1520224
has no clinically significant laboratory or cardiac abnormalities
Description

abnormalities laboratory; abnormalities cardiac

Type de données

boolean

Alias
UMLS CUI [1,1]
C1704258
UMLS CUI [1,2]
C0022877
UMLS CUI [2,1]
C1704258
UMLS CUI [2,2]
C0018787
has a negative serum pregnancy test at screening as is either post menopausal, sterile or willing to use an approved method of contraception.
Description

pregnancy test; Postmenopause

Type de données

boolean

Alias
UMLS CUI [1]
C0032976
UMLS CUI [2]
C0206159
is able to swallow and retain oral medication
Description

oral medication

Type de données

boolean

Alias
UMLS CUI [1]
C0175795
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
has a concomitant medical condition that precludes adequate study treatment compliance or assessment, such as: a. bleeding disorders that would increase risks of additional core biopsy for biomarkers, b. morbid obesity
Description

comorbidity; Hemorrhage; obesity

Type de données

boolean

Alias
UMLS CUI [1]
C0009488
UMLS CUI [2]
C0019080
UMLS CUI [3]
C0028754
is currently receiving treatment with a medication on the prohibited medication list
Description

concomitant medication

Type de données

boolean

Alias
UMLS CUI [1]
C2347852
has allergy to benzamides or inactive components of study drug
Description

hypersensitivity benzamides

Type de données

boolean

Alias
UMLS CUI [1,1]
C0020517
UMLS CUI [1,2]
C0005029
is participating in another clinical trial or has received another investigational agent within 30 days prior to informed consent
Description

Study Subject Participation Status

Type de données

boolean

Alias
UMLS CUI [1]
C2348568

Similar models

Eligibility Breast Cancer NCT00754312

Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Item Group
C1512693 (UMLS CUI)
breast biopsy; mammogram
Item
is scheduled for breast biopsy due to a suspicious mass palpable or ≥1 cm on mammogram
boolean
C0405352 (UMLS CUI [1])
C0024671 (UMLS CUI [2])
Medication dose study
Item
must be able to receive two doses of study medication 7 days apart prior to surgery
boolean
C3174092 (UMLS CUI [1,1])
C0008972 (UMLS CUI [1,2])
Invasive breast carcinoma
Item
has histologically confirmed invasive breast cancer with er positive, er and/or pr negative histology or triple negative (for er, pr, her-2) histology
boolean
C0853879 (UMLS CUI [1])
ecog performance status
Item
has an ecog performance status ≤ 2
boolean
C1520224 (UMLS CUI [1])
abnormalities laboratory; abnormalities cardiac
Item
has no clinically significant laboratory or cardiac abnormalities
boolean
C1704258 (UMLS CUI [1,1])
C0022877 (UMLS CUI [1,2])
C1704258 (UMLS CUI [2,1])
C0018787 (UMLS CUI [2,2])
pregnancy test; Postmenopause
Item
has a negative serum pregnancy test at screening as is either post menopausal, sterile or willing to use an approved method of contraception.
boolean
C0032976 (UMLS CUI [1])
C0206159 (UMLS CUI [2])
oral medication
Item
is able to swallow and retain oral medication
boolean
C0175795 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
comorbidity; Hemorrhage; obesity
Item
has a concomitant medical condition that precludes adequate study treatment compliance or assessment, such as: a. bleeding disorders that would increase risks of additional core biopsy for biomarkers, b. morbid obesity
boolean
C0009488 (UMLS CUI [1])
C0019080 (UMLS CUI [2])
C0028754 (UMLS CUI [3])
concomitant medication
Item
is currently receiving treatment with a medication on the prohibited medication list
boolean
C2347852 (UMLS CUI [1])
hypersensitivity benzamides
Item
has allergy to benzamides or inactive components of study drug
boolean
C0020517 (UMLS CUI [1,1])
C0005029 (UMLS CUI [1,2])
Study Subject Participation Status
Item
is participating in another clinical trial or has received another investigational agent within 30 days prior to informed consent
boolean
C2348568 (UMLS CUI [1])

Utilisez ce formulaire pour les retours, les questions et les améliorations suggérées.

Les champs marqués d’un * sont obligatoires.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial